DyNAbind Enters Collaboration Agreement with Heptares Therapeutics

We’re excited to officially announce our collaboration with Heptares Therapeutics to find new drug candidates for GPCR targets. These membrane bound proteins offer valuable therapeutic opportunities, but have been historically difficult to work with. By combining our technology platforms, we’re ready to tackle this challenge! Check out the press release: